and matrix metalloproteinase-2 (MMP-2). We hypothesized that TIMP-2 binding to INf-NMM generates intracellular sgligand thus regulates cell functions involved in breast carcioma progression. We therefore tested the effect of MI-MMP expression and TIM-2 binding on the Ras/MA kinase signaling pathway, proliferation, migration and iirokinase plasminogen activator expression in humnan mtamrmary carcinoma cells. The results showed that a).TMe-2 binding to ]Nff 1-MMF induces ERKI/2 activation in a dose-dependent manner, b) in contrast, Inhibition of TIM-2 binding to MTfI -MWP abolishes ERKI/2 activation; c) MT1-MMP mutants devoid of the cytoplasnmic tail and/or TIMP-2-binding capacity do not mediate ERKI/2 activation; d) TIN{-2 binding to MT1-MMP stmimlates cell proliferation and migration throughi ERKIt2-dependent mechanisms; e) MTI-MMP expression also controls urolcinase activity throtigh the' ERKI/2 pathway. Thus, TIMP-2 can control mammary carinoma. cell funictions through interaction with its cell membrane receptor, MTl-MMP. This finding may indicate potential new target(s) for I wgc enfo as aimed to inhibit breast cancer progression. 
INTRODUCTION
Me~brane-type I matrix metalloproteinase (MT-MMPs), a mitnber of the MPa family of proteinases, has been implicated in the invasive and metastatic potential of a variety of human malignancies, including mammary carcinoma [1] [2] [3] [4] Unlike the other members of the matrix metalloproteinase (MMv) family, which are secretory proteins, MT1-MMP is a transmembrane proteinase with the catalytic domain exposed on the cell surface and a short, 20 amino acid cytoplasmic domain [5] . On the membrane of a variety of cell types including tumor cells MTl-MMiP forms a tri-molecular complex with MMP-2 and its physiological inhibitor, the tissue inhibitor of metalloproteinases-2 (TIMP-2) [6] . In this complex the N-terminal, inhibitory domain of TIMP-2 directly interacts with the catalytic site of MTl-MMP. The C-terminal domain ofTIMP-2 binds the C-terminal, hemopexin-like domain of MMP-2. Thus, MT1-MMP acts as a membrane binding site for MMP-2.TIMP-2 complex (Fig. 1) .
Binding of the enzyme-inhibitor complex to MTI-NIMP is required for MMP-2 activation [6] . MMP-2 interaction with MT1-MMP has analogy to the high-affinity binding of urokinase plasminogen activator (uPA) to its cell membrane receptor (uPAR) [7] . uPA and uPAR have also been implicated in the invasion and metastasis of a variety oftumors including breast carcinoma [8] [9] [10] [11] .
Although uPAR is not a transmembrane
protein [7, 12] , binding of uPA generates intracellular signals that control cell functions including migration and proliferation through mechanisms independent of the proteolytic activity of uPA [13, 14] . Other transmembrane proteins with short cytoplasmic domains similar to MT1-MMPthe integrins -also generate intracellular signals following interaction with their extracellular ligands [15, 16] (Fig. 2) . To test our hypothesis we constructed an inducible expression system for modulating MT1-M[P expression in breast cancer cells. Human MCF-7 breast carcinoma cells stably transfected with a cDNA for the tetracycline-controlled transactivator (Tet-On and Tet-Off; Clontech) wvere cotransfected with MT1-MM? cDNA in the pTRE vector (Clontech) and with the pTRE2hyg hygromycin resistance vector (Clontech) in both Tet-On and Tet-OffMCF-7 cells. Pools of hygromycin-resistant cells expanded in culture were subcultivated overnight in the absence or in the presence of 1 [Lg/ml of doxycycline, and characterized for MTl-MM'P expression by RT-PCR (not shown) and by Western blotting (Fig. 3) . Consistent with previous reports, multiple forms of MTl-MMIP with Ms 60,000, 58,000 and 43,000 were detected by Western blotting of cell extracts. The 60,000 band is consistent with the size of active MTl-M•P. The 58 kD immunoreactive protein represents an activation product of MWII-MIMP; the 43 kDa band a degradation product of MT1-MMIP. Several transfected cells lines were identified, whose levels of MT1-MMP can be regulated by either addition (Tet-On) or removal (Tet-Off) of doxycycline in the culture medium (Fig. 3) . (Roche) . Molecular masses are shown in kDa on the right. As reported by other authors [17] , our MCF-7 cell transfectants did not produce MT 1-MMP nor MMP-2 (data not shown), and secreted very low amounts of TIMP-2 in the culture medium (data not shown).
. Based on these analogies, we hypthesfted that MT1-MMP binding of TTMP-2 generates intracellular signaling through interaction of the cytoplasmic domain of MT1-MMP with signaling proteins, and thus regulates cell functions involved in breast cancers progression

MT1-MMP expression and TIMT-2 binding induce Ras and ERKI/2 activation with a dosedependent effect.
We then tested the effect ofMT 1-MMP expression on Ras and ERKl/2 activation in the absence and in the presence of exogenous, human native or recombinant TJMP-2. The results showed that MT1-MM expression induced Ras activation. Addition of TIMP-2 (100 ng/ml) resulted in rapid (5 min) Ras activation both in cells that expressed and in cells that did not express MT1-MMIP. However, this effect was transient and could not be detected after 30 min from addition of TIMP-2; Ras activation being maintained only in cells that expressed MTL-MMP (Fig. 4) . MT1-MMP expression resulted in weak activation of ERK1/2. Addition of TIMP-2 (100 ng/ml) to the culture medium induced a rapid and transient (5-15 miin) increase in ERK1/2 activation. This effect was stronger in cells that expressed than in cells that did not express MT1-MMP. No ERKI/2 activation was detected in MTII-MM•+ or MT1-MMP-cells 30 mrin after addition of TIMP-2 ( Fig. 5) . 
TIDMP2 (M1fJ lg[mI)
grown for 24 To characterize the relative contribution ofMT1-MMNP and TllP-2 to ERK activation MT1-MMP TetOn transfectants were incubated with increasing concentrations of doxycycline (0 to I pg/mi). This treatment induced MT1-MMP expression and ERK1/2 activation in a dose-dependent manner. Addition of purified TIMP-2 (100 ng/ml) to the culture medium enhanced ERK1/2 activation (Fig. 6 A) . Addition of doxycycline (1 pig/ml) to MTI-MMP Tet-Off transfectants abolished both MT1-MMP expression and ERK1/2 activation (Fig. 6 B) , showing that ERK1/2 activation did not result from a nonspecific effect of doxycyxihne. In another set of experiments increasing concentrations of TJMP-2 (0 to 300 ng/ml) were added to the culture medium of cells that either expressed or did not express MT1 -MMW, and both cell-associated TIMP-2 and active ERK1/2 were characterized. The results showed that this treatment upregulated both cell-associated TJMP-2 and ERK1/2 activation in a dose-dependent manner in cells that expressed but not in cells that did not express MT1-MNP (Fig. 7) . 
1fl
: complexes were evidenced with the
aT detection system (Roche) .
To test the specificity of TIMP-2 in activating intracellular signaling, we analyzed the effect of TIMP-1, which does not inhibit and binds to MTl-MMP with a much lower affinity than TIMP-2 [19] . In addition, we.tested whether chemical reduction of TIMP-2, which destros its MM2P inhibitory activity, would also affect the capacity of this inhibitor to activate intracellular signaling. The results (Fig. 8) showed that addition of purified TIMP-1 to the culture medium of MTl-MMP-expressing cells did not activate ERK1/2 but actually decreased the level of active ERK1/2 in both MT1-MMP expressing and non-expressing cells. In contrast, chemically reduced TIP-2 showed a stronger effect than native TIMP-2 and also induced ERK1/2 activation in cells that did not express MT1-MMP. This finding is consistent with previous reports showing that TIMP-2 devoid of inhibitory activity retains its capacity to induce cell proliferation [20, 21] .
A Fig. 8 [20, 21] . Inhibition of TIMP-2 binding to cell membrane-bound MT1-MMP abolishes ERK1/2 activation.
We speculated that the observed effect of TIMP-2 on ERK1/2 activation in the absence of MT1-MMP might be mediated by binding of the inhibitor to other MT-MMPs expressed by MCF-7 cells. The MT-MMP class of MMPs currently comprises sis members (MT1-to MT6-MMP). By RT-PCR and Western blotting analysis (not shown) we found that our MCF-7 cells express significant amounts of both MT2-and MT5-MMP. To test our hypothesis that TIMP-2 binding to MT-MMP(s) other than MT1-MMP may induce ERK1/2 activation we tested the effect of reagents that compete with TIMP-2 for binding to the MMP catalytic site. Addition of recombinant, soluble catalytic domain of MT1-MMP (Fig. 9 A) or of Ilomastat (FIg. 9 B) , a low-MW inhibitor that binds to the catalytic domain of MNMs, resulted in dose-dependent decrease of cell-associated TIMP-2 and ERK1/2 activation in MT1-MMP expressing cells. The highest concentrations of soluble MT1-MMP or Ilomastat completely abrogated cell-associated TIMP-2 and ERK1I/2 activation, showing that ERK activation in MCF-7 cells is controlled by TIMP-2 binding to cell surface-associated MMPs. The cytoplasmic tail and TIMP-2 binding capacity of MT1-MMP is required for ERKI/2 activation.
To investigate the mechanisms of signal transduction by MTl-MMP and TIMP-2 we characterized the effect on ERK1/2 activation of mutations in the ecto-and cytoplasmic domains ofMT1-MMP. For this purpose we used: 1) a mutant with a complete deletion of the cytoplasmic domain (A563-582), 2) a mutant with a point mutation (E240A) in the catalytic domain that causes loss of the proteolytic activity, and 3) a mutant with a deletion in the pro domain (A42-46) that abrogates the TIMP-2 binding capacity ofMTl-MMP. These mutants have been described [22, 23] Comparable levels of wt and mutant MT1-MMP were exposed on the cell membrane, as assessed by surface biotinylation of transfected cells (Fig. 11) . Therefore, the observed inability ofthe mutant MT1-MMP transfectants to bind =IM-2 were not because the mutated MT These results showed that ERKl/2 activation requires both the cytoplasmic tail of MTl-MMP and TIIMP-2 binding to the active site of MTlI-NEAP (and/or possibly other transmembrane MT-MMWs). This conclusion is also supported by our finding that soluble MT I-MMP prevents TJMP-2 binding to the cell surface and ERK1/2 activation (Fig. 9A) .
MT1-MMP expression and TTMP-2 binding enhance cell proliferation.
To investigate the biological significance of MTIN-MMAFIP-2-mediated intracellular signaling we characterized the effect of these proteins in cell proliferation, migration, apoptosis and proteinase expression, cell functions involved in tumor growth, invasion and metastasis. Induction of MTI-MiMP expression in Tet-Off or Tet-Off transfectants strongly upregulated PCNA expression (Fig. 12) and stimulated cell proliferation. Addition of purified TIMP-2 to the culture medium enhanced this effect (Fig. 13) . MT1-M P-TIMP-2 interaction stimulates cell migration and proliferation through activation of the ERK1/2 pathway.
Addition of TJMP-2 to the culture medium of MT1-MMLP expressing cells stimulated cell migration in a dose-dependent manner but had no effect with cells that did not express MT1-MMP. Inhibition of ERK1/2 activation with the synthetic inhibitor U0126 blocked TIMP-2-induced cell migration, showing that TIMP-2 -MTl-MMP interaction controls cell movement through activation of the ERX1/2 pathway ( Fig. 14 A and B) . Similarly, inhibition ofERK1/2 activation abolished MTl-MM,'/TBIP-2-induced stimulation of cell proliferation, as assessed by PCNA expression (Fig. 15 
MCF-7 cell apoptosis is not affected by MT1-MMP or TIMP-2
Data shown in our previous report indicated that MT1-MMP expression induced MCF-7 cel apoptosis. These data were not confirmed. Experiments measuring PARP degradation, a marker of apoptosis, with two different antibodies to this protein showed no apoptosis in MCF-7 with or without expression of MTI-MMP. Similarly, addition of TIMP-2 to the culture medium had no effect on MVF-7 apoptosis.
UV :0a Fig. 16 
native PARP (PARP) or only its 85-kDa degradation product (p85 PARP). The membrane was also probed with anti-fl-actin antibody as a controlfor equal loading. Antigen-antibody complexes were evidenced with the ECL detection solution (Roche). MT1-MMP expression (+ or -), indicated on the bottom, refers to samples incubated in the absence or in the presence of doxycycline, respectively
MT1-MMP expression downregulates the level of cell-associated urokinase plasminogen activator.
To investigate potential effects of MT1-MMP/I'MP-2-mediated intracellular signaling on other cell functions involved in tumor invasion, we characterized the expression of urokinase plasminogen activator (uPA) in MT1-MMP Tet-Offtransfectants in the presence or absence of exogenous TIMP-2. uPA, a serine proteinase, has been implicated in the extracellular matrix degradation that occurs in a variety of tissue remodeling processes including tumor invasion [7] . Casein/plasminogen zymography analysis of extracts of MTI-MNIMP Tet-Offtransfectants grown in the presence of doxycycline (i.e. without expression ofMTl-MMP) showed a 55 kDa lytic band that was absent when plasminogen was omitted in the gel (Fig. 17 A) . This observation showed that this lytic band is associated with a plasminogen activator whos" MK is consistent with that of human uPA [7] . Induction &f MT1-MMP expression strongly downregulated the level ofuPA associated with the cell extracts and upregulated the amount of uPA present in the cell-conditioned medium (Fig. 17 B) . Incubation of the cells with ilomastat or with UO 126, a synthetic inhibitor of ERK1/2 activation dramatically upregulated the level of cell-associated uPAboth in cells that expressed and in cells that did not express MT 1-MMP. Addition ofTIMP-2 to the culture medium did not modify this effect (Fig. 17 B) . Thus, MT1-MMP expression downregulates the level of cell-associated uPA through activation of the ERK1/2 signaling pathway. Fig. 17 l~pg) and conditioned medium (20-30 ,i, normalized to the protein concentration of the corresponding cell ex-
tract) were characterized by casein/plasminogen zymography as describedfor panel A.
Other Results.
Membrane-type 1 matrix metalloproteinase (MT 1-MMP) has been implicated as a physiological activator of progelatinase A (NMP-2). We previously reported that plasmin treatment of cells results in proMMP-2 activation and increased type IV collagen degradation [18] . Now we analyzed the role of MT1-MMP in plasmin activation of MMP-2 using HT-1080 cells transfected with MT1-MMP sense or antisense cDNA. Control, vector-transfected cells that expressed endogenous MTl-MMP, and antisense cDNA transfectants with very low levels of MT1-MMP did not activate proMMP-2. Conversely, cells transfected with sense MT1-MMP cDNA expressed high MT1-MMP levels and processed proMMP-2 to 68/66-kDa intermediate activation products. Control cells and MTl-MMP transfectants had much higher levels of cell-associated MMP-2 than antisense cDNA transfectants. Addition of plasmin(ogen) to control or MT1-MMP-transfected cells generated active, 62-kDa MMP-2 but was ineffective with ntisense cDNA transfectants. The effect of plasmin(ogen) was prevented by inhibitors of plasmin but not by metalloproteinase inhibitors, implicating plasmin as a mechanism for proMMP-2 activation independent of the activity of MT1-MMP or other MMPs. Plasmin-mediated activation of proMMP-2 did not result from processing of proMTl-MMP and did not correlate with av 3 3 integrin or TJMP-2 levels. Thus, plasmin can activate proMMP-2 only in the presence of MT1-MMP; however, this process does not require the catalytic activity of MTl-MMP.
The results discussed briefly in this paragraph have been published in The Journal of Cellular Physiology (192: 160-170, 2002) . A reprint is enclosed in the Appendices section of this report KEY RESEARCH ACCOMPLISHMENTS "* Generation of human MCF-7 mammary carcinoma cells that express MT1 -MMP under control by the tetracycline resistance transactivator (Tet-On and Tet-Off). "* MT1-MMP expression and TIMP-2 binding induce Ras and ERK1/2 activation with a dose-dependent effect. "* Inhibition of TIMP-2 binding to cell membrane-bound MTI-MMP abolishes ERKl/2 activation. "* The cytoplasmic tail and TIMP-2 binding capacity of MT1-MMP is required for ERKt/2 activation. "* MT1-MMP expression and TIMP-2 binding enhance cell proliferation and migration. "• MT1-MMP -TIMP-2 interaction stimulates cell migration and proliferation through activation of the ERK1/2 pathway. "* MT1-MMP expression downregulates the level of cell-associated urokinase plasminogen activator. "* Plasmin activates pro-matrix metalloproteinase-2 (proMMP-2) with a MT 1 -MMP-dependent mechansm.
REPORTABLE OUTCOMES
Monea M, Lehti K, Keski-Oja J, Mignatti P. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase dependent mechanism. J. Cell. Physiol 2002, 192: 160-170 .
CONCLUSIONS
The results reported show that MTl-MMP controls a variety of breast cancer cell functions. Some of these effects are mediated by MTI-MMP interaction with its phyAological ligand, T]MP-2. These conclusions are based on the following observations: a) MT1-MMP expression and TJMP-2 binding induce Ras and ERK1/2 activation in a dose-dependent manner; b) in contrast, a synthetic inhibitor of MMPs (Ilomastat) that competes with TIMP-2 for binding to the MTl-MMP active site abolishes ERKl/2 activation; c) MT1-MMP mutants devoid of the cytoplasmic tail and/or TIMP-2-binding capacity do not mediate ERKl/2 activation; d) MTl-MMP expression and TIMP-2 binding stimulate cell proliferation and migration through activation of the ERK1/2 signaling pathway;, e) MT 1-MMP expression downregulates the level of cell-associated urokinase plaminogen activator. These conclusions are schematized in the diagram below. De.vas-dData discussed in our previous report uPA indicated that MT1-MMP-mediated activation of Ras and ERKl/2 occurred in the presence of the synthetic MMV inhibitor llomastat. This effect was modulated in different ways by the addition of TIMP-2 and/or MMP-2 or complex thereof; which also had opposing effects on p 3 8 m activation and induction of apoptosis. These results have not been confirmed in our laboratory, and we believe they reflected experimental flaws. The results described in the present, final report have been repeated numerous times. Some ofthese results are not conclusive and require further investigation, in particular the results showing downregulation of cell-associatated uPA in cells expressing MT I-MMP. Several non-mutually exclusive mechanisms can mediate this effect: decreased expression of the uPA and! or uPA receptor (uPAR) gene, removal of uPAR-bound uPA or increased internalization and degradation of uPAR-bound uPA. Because both uPA and MT l-MNP have been implicated in cell migration, it is tempting to speculate that the opposing modulation of these two proteins reflects a mechanism to coordinate adhesive and/or proteolyticfmnctions that control cell movement.
Our finding also indicate that treatment of tumors with synthetic proteinase inhibitors may result in upregulation of the tumor cell expression of a different family of proteolytic enzymes. If confirmed, this observation may be useful to our designing novel anti-proteolytic treatments aimed at blocking tumor invasion, metastasis and/or angiogenesis.
In conclusion, our data show a novel mechanisms of intracellular signaling mediated by the MT1-MMP/T]MP-2 complex. The activated signaling controls a variety of cell functions involved in tumor growth and invasion. These findings may provide the basis for the development of novel pharmacological tools aimed at inhibiting tumor progression. The matrix metalloproteinases (MMPs) are a family ments for activation. Four menmbrane type MM~s of enzymes involved in a variety of physiological and (MTI-, N12-, MT3-, and MTS-MM~s) have been irn*lpathological processes that require extracellular ma-cated. as physiodlogical proMMP-2'activators. These trix remodeling, such as organogenesis, w'ound repair, MT-bAMs are bound to the cell membranethrough aCtumor invasion., and metastasis. Besides few exceptions, terrmial hydrophobic setpience,`and have thecadtaly'tic Puente et al, 1996) . bovine serum albumin (BSA) (Sigma) as a-tandr&. Membrane-type I matrix metalloproteinase (MT1-Antibody to a 26-residue synthetic pieptde coi.bVesn,-NW), a 63-kDa protein expressed by most cell types ing to the. C-terInhal, intracellulaf ýdain" ffbnn and tissues, processes 72-kDa proMMP-2 into an MTI-MMP (amino Macid residue 557-582) has been de,-intermediate 68/66-kDa form, which may undergo ce The antiodywaspurified by chromatoautocatalytc processing to the active 64/62-kDa form graphy with the antigen coupled to CNBr-activated (Strongin et al, 1993; Atkinson Sepharose 4B (Lohi et at, 1996) . Antibodies to TIhMP-1 et al, 1995; Sato et al., 1996a,b; Will et al, 1996) . How-and -2 were purchased from Calbiochem-Novabiochem ever, this process requires overexpression of MTI-MMP International, antibodies to or and %• integrin chains by transfection or treatment of cells with concanavalin from Chemicon (Temecula, CA) and from Transduction A, phorbol esters, or transforming growth factor f-I Laboratories (Lexington, KY), respectively. (TGF-pl) (Brown et al., 1990; Overall and Sodek, 1990; Atkinson et al, 1995; Lohi et al, Cels and culture medium 1996) . In addition, proMIMP-2 activation by MT1-MMP Human BT-1080 fibrosarcoma cells were originally requires the presence of TIMP-2, although high con-obtained from the American Type Culture Collection centrations of TIMP-2 inhibit proMMP-2 activation (ATCC, CCL-121) and grown in Dulbcco's miium (Strongin et al, 1993; . In the essential medium (DIMEM) supplemented with 10% presence of TIMP-2 tri-molecular complexes consisting fetal calf serum (FCS), 2 mM L-glutamine, 1•0 U/mi of of MT1-IdMP, MMP-2 and TIMP-2 are formed on the penicillin, and 100 pg/ml of streptomycin (GIBCO-BR1L, membrane of HT-1080 fibrosarcoma cells. In these Gaithersburg, MD). complexes, the C-terminal tail of TIMP-2 interacts with the C-terminal hemopexin domain of proMMP-2, and
Transection of HT-1080 cels the N-terminal inhibitory domain ofTIMP-2 binds to the with MTI-MMP CDNA catalytic site of MT1-MMP. MMP-2 also binds to a, The expression plasmids containing nucleotides integrin through its C-terminal domain (Brooks et al., 1-2,369 of MT1-MMP cDNA (pc3SE) or the correspond-1996 Deryugina et al, 2001a) , indicating that ing antisense IcDNA (pc3AS) undertrf nýnzccttionic-MMP-2 interaction with the cellsurface canbemediated trol by the CMV promoter in the pI eNA3 vetor Ihave by multiple binding sites. In addition to activating been descibed (Lohi ,t al, 1996) .. For•--e ýtrans-proMMP-2, recombinant MT1-MMP mutants that lack fection, 8 ml of OPTIF•EM (GIBCO-BRL) was gently the transmembrane domain degrade collagens, gelatin, mixed with 9 pgofeitherpc3 or.pc3SE or pc3ASand 60 fibronectin, and laminin (Pei and Weiss, 1996) .
of Lipofectin (GIBCO-BRL), and the miture was inSeveral serineproteinases like thrombin and neutro-cubated at room temperature for 40 min SUbcdifinent phil elastase, cathepsin G, and proteinase-3 activate RT-1080 cells in 10-cm dishes were washed twice with proMMP-2 by acting in concert with MT1-MMP (Zucker serum-free DME. The mixture was added to the! cells et al., 1995; Galis et al, 1997; Lafleur et at, 2001 ; andincubatedat 37"C for 16 hie.T sw evwased Shamamian et al, 2001). We have previously reported with DME and incubated with 10 ml of D7Mss"Wsplethat components of the urokinase (uPA)-plasminsystem mented with 10%. FCS and .250 1 .nil Afle. ticinf are involved in thecontrol oftype.IVcolagenaseac (Si ma) Geneticin-resistantcell .cloes .wer c on the cell surface. In cell cultures, physiological con-tured in DIE containing 200.pg7nl of *bneidfi Ex-" "centrations of plasmin activate both proMMP-9 and -2 pression of .MT-MMP by the cell clones was analysed without the action of other metallo-or acid proteinases. by Western blotting as described below. On the contrary, in soluble phase, plasmin degrades .. e =i e... both MMP-9 and -2 . To characterPrep on oR-ektra .. ize the cell membrane components-required for plasmmand conditioned med .ia mediated activation of MMP-2, we studied potential HT-1080 cells were seeded into 10-cm culture dishes interaCcionsbetween MTt-MMP, •integdn, TIMP-2, at adensityof2.6 x 1 celldish. The cellwerewashed and plasmin. We report here that proMMP-2 activation twice with phosphatuffered saline.(PBS) tboemiove by plasmin requires expression, but not the catalytic residual FCS, and incubated for 16 h with 4-m/dish of activity of IMT-MMIP and does not correlate with ors serum-freeflM E with or wiu4. 1g/mOf pla and TIMP-2 levels, and/or the indicated concentrationsof 6fe i bitors. The culture supernatants were cei .fged at MATERIALS ANt METHODS .500g at 2C for, 10 min. For gelatin rymo graphy, the Mterials cells were washed twicewithVP3S, lysed for 10min on ice Human plasminogen was purified as described with I mi/dish of Triton X-100, 0.5% (v/v) in 0_tM Tris- (Ossowski et al., 1973; Unkeless et al., 1973) ; gelatin-HC1, pH 8.1 (lysis buffer) under constant shakingand Sepharose (gel-Seph) was purchased from Pharmacia scraped with a rubber policeman. For Westernblotting Biotech AB (Uppsala, Sweden), gelatin from Merck the cells were washed with PBS, scraped with a rubber (Darmstadt, Germany), aprotinin, 1,10-phenanthroline, policeman, centrifuged in an Eppendorf tube for 3 min, and 4-aminophenylmercuric acetate (APMA) from andresuspendedin 100 0loflysisbuffer onice for 10min. Sigma (St. Louis, MO), the MMP-substrate, Mca-For the analysis of TIMP-2 or -1 in cell-conditioned pro-leu-Gly-Leu-Dpa-Ala-Arg-NH1 2 , from Calbiochem-media, 1 ml of serum-free culture supernatant was conNovabiochem International (Schwalbach, Germany). centrated with Centricon tubes. The cell lysates were Protein concentrations were measured by the Bradford centrifuged at 800g for 10minat4 0 C. Conditionedutedia'
162
MONEA E? AL
and cell extrats were immediately analysed by Western fluorimeter (excitatio' max 325 nmn, emission max blotting and/or gelatin-zymography. 393 nm). APMA (1 mM)-treated cell-CM or CM supplemented with EDTA (10 mM) was used as positive or Gelatin zymography negative control, respectively. As a control for the Cell extracts (0.8-1.0mg of protein in 1 ml) or condi-specificity of the assay for the gelatinases, CM was tioned media (4 ml) were incubated at 4°C for I h in an pretreated with gel-Seph as described above and the end-over-end mixer with 25 p1 of gel-Seph equilibrated supernatant of the resin, depleted of the gelatinases, with50InMTris-HC1, 150mMNaC1,5 mMCaC1 2 ,0.02% was tested in the assay. Samples and controls were (v/v) Tween-20, 10 mM EDTA, pH 7.6 (Collier et aL, assayed in duplicate. The total amount of gelatinase 1988). After four washes with 1 ml of equihibrationbuffer activity present in the conditioned media was assessed containing 200 mM NaCl, the beads were resuspended by pre-treating sanmples with APMA as described above. in 30 pl of 4 x non-reducing La~mmli buffer, and loaded By gelatin zymography, APMA treatment resulted in ontoSDS-8%polyacrylamidegelscontaininglmg/mlof complete activation of MMP-2 and -9 (Mazzieri et al., gelatin After electrophoresis, the gels were washed 1997; and data not shown). twice with 200 ml of 2.5% (v/v) Triton X-100 at 220C for 2 h to remove SDS, and three times for 5 minwith H 2 0 to RESULTS remove Triton X-100. The gels were incubated in 50 mM MT1-MMP expression and pro]AP-2 Tris-HCL, 0.2 M NaC1, 20 mM CaC1 2 , pH 7.4 at 3TC for axtivation in HT-p00 cells trano ected 6-12 h, stained overnight with Coomassie Brilliant with MTI-MMP sense or antisense cDNA Blue R-250 0.5% (w/v) in 45% (v/v) methanol, 10% (v/v) acetic acid, and destained in the same solution without
Non-transfected HT-1080 cells and clones of HT-1080 dye (Heussen and Dowdle, 1980) . The M~s of the lysis cells transfected with sense or antisense MTI-MMP bands were determined by reference to high-molecular cDNA, or with the control vector were characterized by mass (14.3-200 kDa) standards (Rainbow Markers; Western blotting with antibody to the intracellular Amersham, Biosciences, Piscataway, NJ).
domain of MT1-MMP. Consistent with previous reports (Lohi et aL, 1996; Lehti et at, 1998 Lehti et at, ,2000 Stanton et aL, Western blotting 1998; Zucker et at, 1998) , multiple forms ofMT1-MMP Concentrated conditioned media or cell extracts with Ms 63,000, 60,090, 58,000, and 4•3,G0 were (80ong)wentraed e onetropnoed india or Spole -t deeted (Fig. 1) . These polypeptides correspond to pro-(80 ag) were electrophoresed in a reducing SDS-poly-and active MTI-tvfMP and further cleavage products of acrylamide gel and electroblotted to a nitrocellulose the enzyme (Lohi et aL, 1996; Lehti et at, 1998 Lehti et at, , 2000 ; membrane (Hybond-C Extra, Amersham). The non- Stanton et al., 1998; Zucker et al, 1998) . specific protein binding sites of the membranes were Non-transfected cells (not shown) or cells transfected saturated in 20 mM Tris base, NaCl 150 mM, 0.1% with the control vector constitntiively expressed 60-and Tween 20, pH 7.4 (TBS-T) containing 5% milk (Carna-58-kDa MT-MMP (Fig. IA) . Under comparable iimution) at 22'C for I h or at 4'C overnight, and reacted at noblotting conditions, the levels of these MT u-f 22CC for l h in TBS-T containing 5% milk and pre-tested forms were dramatically reduced in all the aMitisens dilutions of rabbit antibody to either MT1-MMP or to formsweredr clly red a llttheoontro], the oL, or A3 integrin chains, or mouse anti-TIMP-1 or -2 vector-transfected cells (Fig. IC) . All the clones of cells antibody. The membranes were incubated in TBS-T transfected with the sense cDNA expressed 60-and containing horseradish peroxidase-labeled anti-rabbit 58-kDa bMT-MMP, in addition to the 63-kDa proor anti-mouse IgG (Amersham) at 22'C for 45 min. Each enzyme and the 43-kDa band (Fig. IE) , consistent with stepwas followed by extensive washing in TBS-T (4 ml previous findings that the generation of this peptide :m;) at 22tC. After removing the TBS-T buffer, the is associated with overproduction Of lT1-MMP (Lohi membranes were incubated with 0.125 ml/cmi of ECL a]_, with erproduction of 1 detection solution (Boehringer) at 22WC for 1 min and et at, 1996; Leti et al, 1998 Stanton et at, 19Mo) . exposed to Klms (Hyperfilin MP, Ainersham) for 10 se
The transfected cells were ziýt characteriied -for ep dto m in s (gelatinase expression and activationby gelatin zymongraphy of CM or cell extracts. MMT-9 was present in the 10W activity assay CM of all the trandected cel clones prmarily in its inactive, 92-kDa form. In contrast, the pattern ofMMPThe fluorogenic MMP substrate Mca-Pro-Leu-Gly-2 forms showed significant differences among the Leu-Dpa-Ala-Arg-NHI2-AcOH was dissolved to 1.0 mM different transfectants. Non-transfected HT-1080 cells in dimethylsulphoxide as described (Knight et aL, 1992) (not shown) and cells transfected with the vector alone, and stored at 4VC in the dark to avoid photo-oxidation. which constitutively express active (60-kDa) MTITo measure gelatinase activity, the substrate was MMP, secreted MMP-2 only in its 72-kDa proenzyme diluted to 10 pM in 50 mM Tris-HCI, 0.2 M NaC1, form as did antisense cDNA transfectants that express 20 mM CaCl 2 pH 7.4 (assay buffer). Increasingvolumes very low amounts of MT1-MMP (Fig. 1BD) . In contrast, (10-300 pI) of control medium or cell-conditioned in the CM of cells transfected with MTi-MMP cDNA 68/ medium (CM) were added to 500 pl of assay buffer con-66-kDa MMP-2 was detected in addition to the 72-kDa taining the substrate, and the reaction mixture was proenzyme (Fig. IF) . Consistent with previous reports, incubated at 3VC in the dark for 30 min to 6 h. At the MMP-2 activation correlated with the overexpression end of the incubation, the reaction was blocked by addi-of 63-and 60-kDa MT1-MMP and with the generation tion of 500 pi of 10% acetic acid. The reaction pro-of the 43-kDa form of MTI-MMP (Lehti et aL, 1998 ; duct was measured as described, using a FluoroMax- 2 Stanton et al., 1998 
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Likwise theleves ofthe g -td.tintegrinchIns wer B convesdeallor in te he fMrl-MP transectantsthand oetirther cell cimloae (Fig.B Thus neuofe condi-tio tioned mhred iaia()on of-08 cell sclnes trlanseced it in'i~ onsfwand aIpparesulbtwed fromP inreas edel MM? atvth cen eDNA (SE), the corresponding antisense cDNA (AS), or the empty the MT1-I~MW transfectants, the cells were grow'n -in vector (Control). MTI-KWd expression by the indicated cell clones is the presence of the MMP inhibitor Marimastat (10 pMA).
shown in Figure 1 . Conditioned media and cell extracts were analyzedIntersecofarattheMofllhelns by gelatin zymography as described under Materials and MethodsIntepsncofMrmtaheCofllhelns section-Molecular masses are shown in kDa on the left-This mgperi-contained comparable levels of TIDIP-2 (Fig. 3B) , irament was repeated twice with comparable results.
plicating ME, activity in TIMF-2 dowliregulation.- In contrast, Marimastat bad no effect on ot,0 levels, degradation of a specific fluorogenic substrate and by indicating that a, and N gene expression may be gelatin zymography, as described under Materials and downregulated in MT1-~MNP transfectants. Methods section. Plasmin-mediated prolb1MP-2 activation i
To assess the linearity of the fluorogenic assay' depedenton MI-M P epresionincreasing volumes (10-300 1 d) of medium conditioned dependmtonby ncon-transfected HIT-1080 cells in the absence or in Plasmin has been shown to activate proMMP-2 in the the presence of plasmninogen (4 pg/min) were diluted in presence, but not in the absence of cells, sugesting a 500 pl of assay buffer and incubated in the presence of role for the cell surface in this process (Mazzieri et al. , the substrate (10 pM) for 30 min to 3 h. The assay was 1997). To investigate the potential role of MT1-MMP linear with volumes of CM ranging 10-1100 p1 and in plasmirt-mediated proMMP-2 activation, the trans-incubation times raging 0.5-3.0 hi (Fig. 4) . Additio'n of fected cell clones were incubated in the presence or EDTA to the reaction mixture or depletion of the absence of plasminogen (4 pg/nil) for 16 h. HT-1080 cells gelatinases from the CM by gel-Seph chromatography secrete high levels of uPA that rapidly convert plasmni-as described under Materials and Methods blocked nogen into plasmin ; and data not substrate degradation (Fig. 5) , showing the specificity of shown). Gelatinase activation was analysed both by the assay for the gelat~inases.'Consistent with previous. findings (Mazzieri et a1, 1997) , medium conditioned other clones, showing that the lower ativity mieasuzed by non-transfected RT-1080 cells In the presence of in the presence of plasmin(ogen) was not becanse of plasmin(ogei) slh-wed a 4.5-fold increase in gelatinase higher TIMP-2 or -1 levels. With the tiihr tqpis of (MMP-2 and -9) activity relative to medium conditioned transfectants substrate deradiatin was. competely in the absence ofplasminogen (Fig. 4) . abolished by EDTA or pIN-treaitment of th•ecolkd ned The activity produced by the control cells in the media with gel-Seph, showing that -the-ctiit aeapresence of plasmin(ogen) (-40% of the total, APMA-sured was mediated exclusively bygelatinases. activatable gelatinase activity) was similar to that ofthe By gelatin zymography, medium conditioned in the MT1-MM? transfectants in the absence of plasmin absence of plasmin(ogen) by cells overexpressing MT1-(ogen) (Fig. 5) . The levels of total, APMA-activatable MMW (Fig. 6, MT1 -MMP SE) showed three MMP-2 gelatinase activity of these two clones were comparable bands of 72, 68/66, and 64/62 kDa. Control, vector-(see Fig. 5 ). Addition of plasmin(ogen) to MT1-MMP transfected cells V), and antisense cDNAtransfectants transfectants increased the gelatinase activity to ap-(MTN-M£P AS) showed only one 72-kDaban& Addition proximately 75% ofthe total APMA-activatable activity, of plasmin(ogen) to the culture medium -of antisense In contrast, plasmin only increased the gelatinase cDNAtransfectants had no effect on proMNP-2 activaactivity of the antisense transfectants to approximately tion, although it generated active 84/82-kDa MlF-9 20% of the total activity (Fig. 5) . The total APMA- (Fig. 60) . In contrast, addition of plasmin(ogen) to the activatable gelatinase activity of antisense transfec-culture medium of control cells or MT1-MMP transfectants was approximately 30% higher than that of the tantsgenerated active, 64!62-kDaMMP-2 (Fig.6AB,) fectants by the biotin-avidin method (Lehti et aL, 1998) followed by inmmunoprecipitation after different incubation times (30 min-6 h) in the presence or absence of C varying amounts of plasmin(ogen) (data not shown).
Plasmin also had no effect on the levels of a or 03 integrin chains expressed by the three cell lines Ph~ inogen---. ÷...4- (Fig. 7AB ), but further downregulated the low levels of =IMP-2 present in the CM of the MTI-MMP transfectants (see Fig. 3A ). Conversely, in the other two clones, which expressed considerably higher /-5 0 amounts of TIMP-2, plasmin did not significantly affect the levels ofthis inhibitor (Fig. 7C) . By inmunoblotting, V degradation products of TIMP-2 could not be detected in Sthe medium of any of the cell clones. Thus, plasmin activation of proMMP-2 does not appear to be mediated in decreased 68166-1Da MMP2 (FIg.M) . This observation is consistent with previous findings &a the processing of proMIVIP-2to 68/66 kDa-isl Mr1-NPadependent and that conversion to fully active, 62-kDa The plasmin-mediated conversion of 72-64/62-kDa MMP-2 occurs through autocatalysis (Sato et at., MMP-2 was less efficient with control, vector-transfect-1996ab). Addition of plasminogen in the presence or edoells than withthe MTI-MMP transfectants (Fig. 6D) . absence of the metalloproteinase inhibitors resulted in With the MT1-MMP overexpressing cells, plasmin fully the conversion of the 68/66-kDa form to 64/62-.Da converted the 68/66-kDa intermediate activation pro-MMP-2, indicating that plasmin can catalyze the duct of MMP-2 to active, 64/62-kDa MMP-2 (Fig. 6D) . generation of active 62-kDa MMP-2 under conditions Thus, plasmin generates active MMP-2 in cells that in which MTI-MMP activity and/or autocatalysis are express MT1-MMP, but has no effect on proMMP-2 inhibited. Conversely, the effect of plasmin(ogen) was secretedby cells with very low levels (or virtually devoid) inhibited by addition of aprotinin (100. g'ml), a serine of MT1-MMP.
proteinase inhibitor that blocks plasmin activity In the presence of plasmin(ogen) antisense transfec- (Fig. 6AB ). As addition of aprotinin alone has no effect tants had no active MMP-2, but secreted 84/82-kDa on the gelatinases and data not MMP-9 (Fig. 6C) , suggesting that the low gelatinase shown), these findings showed that plasmin directly activity measured by the fluorigenic substrate assay in catalyzes the generation of 64/62-kDa MMP-2 from the the presence of plasmin(ogen) was mediated by acti-68/66-kDa form generated by MT1-MMP and from the vated MMP-9. MTI-MMP transfectants had a level of 72-kDa proenzyme. MT -DM and/or with the generation of the 43-kDa clevage prodkuct (Lohi et al.,  ..... ................... .... MMP-2 binding to and activation on the. cell surface Brooiks ' at, 199, 1998;  . Ukewise, TIMP-2 levels did not creaewith 1080 ME transfectants grown ia the absence ori teprsnc l plasWmin-Mediated proMM-2 activation. :Gekinas plasmin(ogen). liT.1080 cels transfected with either the 'vector TWJd-2 downregulation in MT1-MlP transfectants was abolished by addition of the MM? inhibitor marimastat, whereas m46s integrin downregulation was hiotDISUSSONBecause this phenomenon wa consistent in sev'eral DISCUSIONtransfectant clones, it is un~likely to simply reflect clonal' The data reported show several features of M]21-variability. Maquoi et al. (2000) have describdT1 MWP-plaszmn interactions in proMMP-2 activation: MMP2-dependent internalization and rapid inti'acel-(a) WINNMM and plasmin act in concert to activate lular degradation of TllvP-2 in HT-1080 cells that ProlMNP-2, (b) plasmin activation of proMMP-2 re--overexpress MT1-MMP. Based on these findings, quires the expression, but not the catalytic activity of Marimastat, which has an inhibit-ion constant to the M'T1-MMP; (c),cell-associated proMMP-2 is activated MT1-NMP catalytic -domain in the low nanomolar range, can compete with TIMP-2 binding to the MT1-cleavage of the C-telninal, hem6pexin-like domain MMW catalytic site (Toth et al., 2000) . As a result, of proMMP-2. Such cleavage would not affect the marimastat can inhibit subsequentTIMP-2 internaliza-N-terminal pro domain, but would account for the detion and degradation. However, at downregulation crease in M 7 observed by zymography. In addition, cleawas not prevented by marimastat, suggesting that this vage in the hemopexin domain would prevent TIMP-2 effect of MTl-MMP overexpression may be mediated binding, which would result in increased activity of through a non-catalytic mechanism(s). In contrast to M2P-2 activated by other mechanisms. However, in recent reports (Deryugina et al., 2000 (Deryugina et al., , 2001b ; Ratnikov this scenario, active MMP-2 should have Mr lower than et al., 2002), we did not observe MT1-MMP-mediated 62,000 as activation would entail cleavage in both the processing of af6 integrin.
pro and the C-terminal peptide. Our finding that plasmin can downregulate TIMP-2 ThelowTIMP-2 levels ofourMTl-MMP transfectants and -1 levels indicates a novel role for plasmin in the may account for the high MMP-2 activity of these cells control of MMP activity. Plasmin not only activates (Fig-5) . However, proMMP-2 activation was also desome MMPs (Werb et al., 1977; He et al, 1989 ; Okada tected by zymography (Fig. 6) , showing that MMP-2 et al., 1990 MMP-2 et al., , 1992 Murphy et al, 1992a; Nagase, 1996) , processing indeed occurs in the presence of plasmin. In but can also increase their activity by downregulating addition, increasedgelatinase activity was also obtained MM inhibitors. In the case ofMMP-2, whose activation by addition of plasmin(ogen) to control cells that have depends on T1MP-2 levels , relatively high TIMP-2 levels (Figs. 4 and 5) . We cannot plasmin control of T=MP-2 results in the regulation of rule out that TfMP-2 degradation by plasmin may both MMP-2 activation and catalytic activity, contribute to increasing MMP-2 activation and activity. Consistent with our previous finding that plasmin However, addition of plasmin(ogen) to antisense cDNAactivation of proMMP-2 does not require the action of transfected cells, which have TIMP-2 levels comparable metallo-or acid proteinases , to that of control cells, did not result in proMMP-2 with our HT1080 cell transfectants plasmin-mediated activation and increased gelatinase activity. This findactivation of proMMP-2 occurred in the presence of ing rules out the hypothesis that TWMP-2 degradation the metalloproteinase inhibitors 1, 10-phenanthroline is the only mechanism by which plasmin mediates in- (Fig. 6 ) or batimastat (data not shown). These inhibitors creased MMVP-2 activation and activity. also blocked the generation of 68/66-kDa MMP-2 by Addition of plasminogen to control or artisense cDN-A cells that overexpress MT1-NMP, showing that they transfectants resulted in proMMP-9 activation, but did indeed block MT1-MMP activity. MT1-MMP activ-had no effect on the proMMP-9 secreted by MTI-MMP ity and/or MMP-2 autocatalysis were not involved in transfectants (Fig. 6 ). This effect was observed several plasnin-mediated activation of proMMP-2. The exact times in a reproducible manner. The reason for the mechanism(s) by which these inhibitors interfere with lack of proMMP-9 activation by plasmin in MT1-MMP TIMP-2 binding to MT1-MMP remain unclear. Be-transfectants is not clear. We have previously reported cause TIMP-2 affinity to MT1-MMP is slightly higher that MMP-9 activation also requires the presence of the than that of marimastat, sufficient formation of MT1-cell surface . We hypothesize that MMP.TIMP-2.MMP-2 complexes may occur to allow the high levels of MTi-MMP in transfected cells localize plasmin activation of bound proMMP-2.
higher amounts of MMP-2 on the cell membrane than Plasmin had no effect on MT1-MMP activation, as in non-transfected cells. Membrane-assocated MEAP-2 demonstrated by Western blotting analysis and sutrface may compete with MMP-9 for plamain eitherbecause it labeling experiments (data not shown). Others have is in excess of MMP-9 or because MT1-MMP-bouni reported that plasmin catalyzes the conversion of a MMP-2 is activated by plasmin more efficiently than recombinant GST-proMTI-MMP fusion protein into a MMP-9 (e.g., MMP-2 maybe spatially closerthan MMNcatalytically active enzyme able to activate proMMP-2 9 to cell surface-associated plasmin). (Okumura et al, 1997) . In cells, MT1-MMP is activated MTIl-MMP has been proposed to be a -physiological intraceliularly during transport to the plasma mem-activator" of proMMP-2. However, proMMP-2 activabrane. It is possible that unlike soluble MT-MMP, tion by MT1-MMP occurs only in cells that overexpress membrane-anchored MT1-MMP is protected from pro-MT1-MMP following transfection or treatment with teolytic cleavage by plasmin (Pei and Weiss, 1996; Sato PMA or Con A, reagents that also upregulate other et al, 1996ab; Pei, 1999a,b) . proteinases in many cell types (Overall and Sodek, 1990-, ProMMP-2 can also be activated by stromelysin- 1 Strongin et al, 1993; Atkinson~et aL, 1995; Lohi etal., (MMP-3) (Miyazaki et al., 1992) or by matrilysin 1996). In addition, although MT1-MMP is expressed by (MMP-7) (Crabbe et al, 1994) . Our HT-1080 cells a variety of cell types, only some express active M! -2 express no MMP-3, as assessed by casein zymography (Lohi and Keski-Oja, 1995; Yu et al, 1995; Theret et al., and Western blotting (data not shown). Plasmin might 1997). These findings raise important questions as to activate prMMP-2 indirectly by "unmasking" MT1-the quantitative and qualitative requirements for MT1-MNW on the cell membrane, for example, by cleaving MMP-mediated activation of proMMP-2: is upregulamolecules associated with it and making it available tion of MT1-MMP required for proMMP-2 activation or for interaction with the substrate. However, our finding are other factors involved? In a variety of tumors, MT1-that plasmin activates proMMP-2 in the presence of 1, MMP expression has been correlated with the presence 10 phenanthroline, EDTA or of active MMP-2 (Tokuraku et al., 1995; Yamamoto Batimastat strongly indicates that plasmin acts directly et aL, 1996) . However, all these studies have not on proMMP-2 or proMMP-2 TIMP-2 complex. A possi-quantitated MT1-MMP relative, for example, to normal ble mechanism of action could also consist of plasmin tissues; in addition, they have not considered the 
